EGFR and glioblastoma: Based on this, a phase I clinical evaluation of EGFR-targeted, doxorubicin-loaded minicells (EGFR(V)-EDV-Dox) was performed in human patients with recurrent glioblastoma in Australia and another phase I trial # NCT02766699 is currently under progress in the USA.